TY - JOUR
T1 - Intravenous human immunoglobulin treatment of serum from HLA-sensitized patients in kidney transplantation
AU - Picascia, Antonietta
AU - Grimaldi, Vincenzo
AU - Paolillo, Rossella
AU - Vasco, Maria
AU - Casamassimi, Amelia
AU - De Luca, Francesco Paolo
AU - Cavalca, Francesco
AU - Schiano, Concetta
AU - Napoli, Claudio
PY - 2014
Y1 - 2014
N2 - Objective: Intravenous immunoglobulin (IVIG) products are known to have beneficial immunomodulatory effects on several inflammatory and autoimmune disorders. These effects could be attributed to a different inhibitory action on complement factors, but other mechanisms could be implicated, e.g., immunocomplexes development and/or anti-idiotypic antibodies. Positive results on the reduction of anti-Human Leukocyte Antigens (HLA) antibodies in highly sensitized patients have also been found. The present study focuses on the effect of IVIG on the reduction of Panel Reactive Antibody level and crossmatch positivity in sensitized patients awaiting kidney transplantation. Methods: The study was performed adapting an in vitro assay on sensitized patients' sera in waiting list for kidney transplantation. Sera of twelve highly sensitized patients were evaluated for the cytotoxicity inhibition after 10% IVIG treatment. Results: A reduction of anti- HLA antibody levels was observed in 75% (9/12) of treated patients in vitro, while 25% (3/12) resulted unresponsiveness. Particularly, our data showed a significantly higher Panel Reactive Antibody reduction for T lymphocytes (p
AB - Objective: Intravenous immunoglobulin (IVIG) products are known to have beneficial immunomodulatory effects on several inflammatory and autoimmune disorders. These effects could be attributed to a different inhibitory action on complement factors, but other mechanisms could be implicated, e.g., immunocomplexes development and/or anti-idiotypic antibodies. Positive results on the reduction of anti-Human Leukocyte Antigens (HLA) antibodies in highly sensitized patients have also been found. The present study focuses on the effect of IVIG on the reduction of Panel Reactive Antibody level and crossmatch positivity in sensitized patients awaiting kidney transplantation. Methods: The study was performed adapting an in vitro assay on sensitized patients' sera in waiting list for kidney transplantation. Sera of twelve highly sensitized patients were evaluated for the cytotoxicity inhibition after 10% IVIG treatment. Results: A reduction of anti- HLA antibody levels was observed in 75% (9/12) of treated patients in vitro, while 25% (3/12) resulted unresponsiveness. Particularly, our data showed a significantly higher Panel Reactive Antibody reduction for T lymphocytes (p
KW - Desensitization of patient sera
KW - Intravenous immunoglobulin
KW - Kidney transplantation
KW - Panel reactive antibody
KW - Sensitized patients
UR - http://www.scopus.com/inward/record.url?scp=84899011056&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84899011056&partnerID=8YFLogxK
U2 - 10.3109/0886022X.2014.880326
DO - 10.3109/0886022X.2014.880326
M3 - Article
C2 - 24456257
AN - SCOPUS:84899011056
VL - 36
SP - 585
EP - 588
JO - Renal Failure
JF - Renal Failure
SN - 0886-022X
IS - 4
ER -